Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Hypocrellin B** is a fungal perylenequinone pigment isolated from *Hypocrella bambusae* and *Shiraia bambusicola*. It serves as a potent photosensitizer for photodynamic therapy (PDT) and sonodynamic therapy. Upon light activation, hypocrellin B generates reactive oxygen species (ROS) including singlet oxygen and superoxide, inducing apoptosis and necrosis in tumor cells and microbes. It has been investigated for anti-tumor, anti-viral (including against SARS-CoV-2 and HIV), antimicrobial, and antileishmanial activities. Studies report apoptotic and antiproliferative effects in cancer cell lines (breast, lung, esophageal, ovarian, nasopharyngeal), and it is non-toxic in the dark but becomes cytotoxic upon irradiation, supporting immune stimulation via inflammatory responses. Traditionally, it has use in Chinese medicine and is under exploration for nanoformulation strategies to improve bioavailability and efficacy in PDT[1][2][4][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on hypocrellin B.